Suppr超能文献

来自加德满都三级医院的铜绿假单胞菌分离株的抗菌耐药模式。

Antimicrobial Resistance Pattern of Pseudomonas aeruginosa Isolates from Tertiary Care Hospitals in Kathmandu.

机构信息

Central Department of Microbiology, Tribhuvan University, Kathmandu, Nepal.

Department of Microbiology, Maharajgunj Medical Campus, TU Teaching Hospital Maharajgunj, Kathmandu, Nepal.

出版信息

Kathmandu Univ Med J (KUMJ). 2023;21(84):429-435.

Abstract

Background Antimicrobial resistance, caused by Pseudomonas aeruginosa (P. aeruginosa), poses a global health threat, limiting treatment options and increasing morbidity and mortality rates due to its intrinsic and multidrug resistance. Objective To determine the antimicrobial resistance patterns of P. aeruginosa isolates from patients visiting or admitted to tertiary care hospitals in Kathmandu. Method A cross-sectional study was conducted at Bir Hospital and Tribhuvan University Teaching Hospital (TUTH) from December 2021 to December 2022. Isolates were identified and tested for antibiotic susceptibility following standard microbiological guidelines. Result The antimicrobial resistance of 200 P. aeruginosa isolates increased from low to high levels, as per the recommended anti-pseudomonal antibiotics by the Clinical and Laboratory Standards Institute (CLSI), from 0% to 94%. piperacillin/tazobactam exhibited significantly lower resistance at 18(9%) and while considerably higher resistance was observed with ceftazidime at 188(94%) compared to different antibiotics, followed by amikacin 34(17%), imipenem 58(29%), ciprofloxacin 42(21%), aztreonam 51(25.5%), and fosfomycin 44(22%). No resistance was observed to colistin and polymyxin B. P. aeruginosa resistant to carbapenem was accounted for 33.5% of the total, and multidrug resistance categories included multidrug resistance (MDR) at 39.0%, extensively drug resistance (XDR) at 13.5%, and P. aeruginosa difficult-to-treat (DTR PA) at 4.6%. Conclusion Most of the isolates were resistant to anti-pseudomonal antibiotics; however, colistin, polymyxin B, amikacin, doripenem, piperacillin/tazobactam, and fosfomycin were effective against MDR P. aeruginosa. Regular surveillance measures are essential to manage antimicrobial resistance.

摘要

背景

铜绿假单胞菌(P. aeruginosa)引起的抗菌药物耐药性对全球健康构成威胁,由于其固有和多药耐药性,治疗选择受限,发病率和死亡率增加。

目的

确定来自加德满都三级保健医院就诊或住院患者的铜绿假单胞菌分离株的抗菌药物耐药模式。

方法

2021 年 12 月至 2022 年 12 月在比尔医院和特里布万大学教学医院(TUTH)进行了一项横断面研究。按照标准微生物学指南对分离株进行鉴定和抗生素药敏试验。

结果

根据临床和实验室标准研究所(CLSI)推荐的抗假单胞菌抗生素,200 株铜绿假单胞菌分离株的抗菌药物耐药性从低到高,耐药率从 0%到 94%不等。哌拉西林/他唑巴坦的耐药率显著较低,为 18(9%),而头孢他啶的耐药率则明显较高,为 188(94%),与其他抗生素相比,阿米卡星耐药率为 34(17%),亚胺培南耐药率为 58(29%),环丙沙星耐药率为 42(21%),头孢他啶耐药率为 51(25.5%),磷霉素耐药率为 44(22%)。未观察到对黏菌素和多黏菌素 B 的耐药性。碳青霉烯类耐药的铜绿假单胞菌占总数的 33.5%,多药耐药类别包括多重耐药(MDR)占 39.0%,广泛耐药(XDR)占 13.5%,难治性铜绿假单胞菌(DTR PA)占 4.6%。

结论

大多数分离株对抗假单胞菌抗生素耐药,但黏菌素、多黏菌素 B、阿米卡星、多利培南、哌拉西林/他唑巴坦和磷霉素对 MDR 铜绿假单胞菌有效。需要定期进行监测措施来管理抗菌药物耐药性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验